BIO-PATH HOLDINGS Files Routine 8-K, Confirms Nasdaq Listing
Ticker: BPTH · Form: 8-K · Filed: Jan 10, 2024 · CIK: 1133818
| Field | Detail |
|---|---|
| Company | Bio-Path Holdings Inc (BPTH) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: compliance, corporate-governance, regulatory-filing
TL;DR
**BPTH filed a routine 8-K, no big news, just standard compliance.**
AI Summary
BIO-PATH HOLDINGS INC filed an 8-K on January 10, 2024, primarily to disclose general corporate information and confirm its registration on The Nasdaq Capital Market under the trading symbol BPTH. This filing is a routine update, indicating no major new events but rather a reaffirmation of their current status and compliance with SEC regulations. For investors, this means there are no immediate red flags or significant positive developments reported in this specific filing, suggesting a neutral impact on stock valuation based solely on this document.
Why It Matters
This filing is a standard compliance update, reassuring investors that BIO-PATH HOLDINGS INC continues to meet its regulatory obligations and remains listed on a major exchange.
Risk Assessment
Risk Level: low — This 8-K is a routine administrative filing with no new material information that would introduce significant risk.
Analyst Insight
A smart investor would note this as a routine compliance filing, indicating no immediate catalysts or red flags. Further research into BIO-PATH HOLDINGS INC's financial statements and other filings would be necessary for any investment decision, as this 8-K provides minimal new information.
Key Numbers
- $0.001 — par value per share (This is the stated par value for BIO-PATH HOLDINGS INC's common stock.)
Key Players & Entities
- BIO-PATH HOLDINGS INC (company) — the registrant filing the 8-K
- The Nasdaq Capital Market (company) — the exchange where BIO-PATH HOLDINGS INC's common stock is registered
- BPTH (company) — the trading symbol for BIO-PATH HOLDINGS INC
- January 10, 2024 (date) — date of the earliest event reported and filing date
- Delaware (company) — state of incorporation for BIO-PATH HOLDINGS INC
- 001-36333 (dollar_amount) — Commission File Number
- 87-0652870 (dollar_amount) — IRS Employer Identification No.
- 4710 Bellaire Boulevard , Suite 210 , Bellaire , Texas 77401 (company) — address of principal executive offices
- (832) 742-1357 (dollar_amount) — registrant's telephone number
- $0.001 (dollar_amount) — par value per share of Common Stock
FAQ
What is the primary purpose of this 8-K filing by BIO-PATH HOLDINGS INC?
The primary purpose of this 8-K filing, dated January 10, 2024, is to provide a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, essentially a routine disclosure of general corporate information and confirmation of their registration on The Nasdaq Capital Market.
On which stock exchange is BIO-PATH HOLDINGS INC's common stock registered?
BIO-PATH HOLDINGS INC's Common Stock, with a par value of $0.001 per share, is registered on The Nasdaq Capital Market under the trading symbol BPTH.
What is the trading symbol for BIO-PATH HOLDINGS INC?
The trading symbol for BIO-PATH HOLDINGS INC's Common Stock is BPTH.
What is the state of incorporation for BIO-PATH HOLDINGS INC?
BIO-PATH HOLDINGS INC is incorporated in Delaware.
Does this 8-K filing indicate any significant new events or changes for BIO-PATH HOLDINGS INC?
No, this 8-K filing does not indicate any significant new events or changes. It is a routine filing that primarily confirms existing corporate details and compliance, without reporting any material new developments.
Filing Stats: 446 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2024-01-10 16:10:09
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share BPTH The Nasdaq Capital M
Filing Documents
- bpth-20240110x8k.htm (8-K) — 37KB
- bpth-20240110xex99d1.htm (EX-99.1) — 14KB
- bpth-20240110xex99d1001.jpg (GRAPHIC) — 13KB
- 0001558370-24-000184.txt ( ) — 192KB
- bpth-20240110.xsd (EX-101.SCH) — 3KB
- bpth-20240110_lab.xml (EX-101.LAB) — 16KB
- bpth-20240110_pre.xml (EX-101.PRE) — 10KB
- bpth-20240110x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 10, 2024, Bio-Path Holdings, Inc. (the "Company") issued a press release titled, "Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients." A copy of such press release is attached hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Press release dated January 10, 2024. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-PATH HOLDINGS, INC. Dated: January 10, 2024 By: /s/ Peter H. Nielsen Peter H. Nielsen President and Chief Executive Officer